Teleflex (NYSE:TFX) Given “Hold” Rating at Needham & Company LLC

Teleflex (NYSE:TFX)‘s stock had its “hold” rating reiterated by research analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports.

A number of other research firms also recently issued reports on TFX. StockNews.com downgraded Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Morgan Stanley cut their target price on Teleflex from $275.00 to $191.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Wells Fargo & Company decreased their price target on Teleflex from $214.00 to $146.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Truist Financial dropped their price objective on Teleflex from $200.00 to $149.00 and set a “hold” rating on the stock in a research note on Monday, March 3rd. Finally, Piper Sandler reiterated a “neutral” rating and issued a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $182.63.

Teleflex Price Performance

Shares of NYSE:TFX opened at $139.25 on Wednesday. Teleflex has a twelve month low of $128.55 and a twelve month high of $249.90. The stock’s 50 day moving average is $169.58 and its 200-day moving average is $199.60. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of 27.68, a PEG ratio of 1.73 and a beta of 1.21.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, topping the consensus estimate of $3.86 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The firm had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. Sell-side analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Institutional Trading of Teleflex

A number of large investors have recently added to or reduced their stakes in TFX. Apollon Wealth Management LLC grew its position in shares of Teleflex by 3.7% during the 3rd quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock valued at $377,000 after acquiring an additional 55 shares during the period. SRS Capital Advisors Inc. grew its holdings in Teleflex by 0.3% during the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company’s stock valued at $4,844,000 after purchasing an additional 60 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its holdings in Teleflex by 4.5% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,517 shares of the medical technology company’s stock valued at $375,000 after purchasing an additional 66 shares during the period. HighTower Advisors LLC increased its position in Teleflex by 1.7% in the third quarter. HighTower Advisors LLC now owns 3,998 shares of the medical technology company’s stock worth $986,000 after buying an additional 66 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of Teleflex by 0.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 20,320 shares of the medical technology company’s stock valued at $3,614,000 after buying an additional 74 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.